Oncostatin-M functionalized cryogel microspheres for promoting diabetic bone defects regeneration

The ability of OSM/MS to promote endogenous stem cell recruitment, modulate the immune-osteogenesis microenvironment, and induce angiogenesis makes it a potent candidate for diabetic bone defects. The injectable and porous nature of OSM/MS facilitates minimally invasive delivery and integration with the irregular bone defect site. In particular, OSM/MS face fewer regulatory hurdles compared with traditional tissue engineering strategy due to the lack of cellular components. Given the significant unmet clinical need and the promising in vivo results, OSM/MS holds great potential for transforming the treatment paradigm for bone defects in diabetic patients.